Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's).

Clowse ME, Copland SC, Hsieh TC, Chow SC, Hoffman GS, Merkel PA, Spiera RF, Davis JC Jr, McCune WJ, Ytterberg SR, St Clair EW, Allen NB, Specks U, Stone JH; WGET Research Group.

Arthritis Care Res (Hoboken). 2011 Dec;63(12):1777-81. doi: 10.1002/acr.20605.

2.

Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.

Mok CC, Chan PT, To CH.

Arthritis Rheum. 2013 Jan;65(1):206-10. doi: 10.1002/art.37719.

3.

Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.

Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, Christman GM, Somers EC.

Gynecol Endocrinol. 2012 Aug;28(8):624-7. doi: 10.3109/09513590.2011.650752. Epub 2012 Feb 2.

4.

Etanercept plus standard therapy for Wegener's granulomatosis.

Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.

N Engl J Med. 2005 Jan 27;352(4):351-61.

5.

Ovarian reserve parameters: a comparison between users and non-users of hormonal contraception.

Bentzen JG, Forman JL, Pinborg A, Lidegaard Ø, Larsen EC, Friis-Hansen L, Johannsen TH, Nyboe Andersen A.

Reprod Biomed Online. 2012 Dec;25(6):612-9. doi: 10.1016/j.rbmo.2012.09.001. Epub 2012 Sep 16.

PMID:
23069740
6.

The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels.

Benian A, Guralp O, Uzun DD, Okyar A, Sahmay S.

Gynecol Endocrinol. 2013 Mar;29(3):226-9. doi: 10.3109/09513590.2012.738725.

PMID:
23428228
7.

Age at menarche: a predictor of diminished ovarian function?

Weghofer A, Kim A, Barad DH, Gleicher N.

Fertil Steril. 2013 Oct;100(4):1039-43. doi: 10.1016/j.fertnstert.2013.05.042. Epub 2013 Jun 27.

PMID:
23809497
8.

A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis.

Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M.

Arthritis Rheum. 1997 Dec;40(12):2187-98.

PMID:
9416856
9.

[Assessment of ovarian reserve with anti-Müllerian hormone in female patients with systemic lupus erythematosus].

Chen D, Yuan S, Zhan Z, Zhan Y, Yang X, Liang L.

Zhonghua Yi Xue Za Zhi. 2014 Apr 8;94(13):977-80. Chinese.

PMID:
24851682
10.

Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience.

Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, Karafa MT, Roberson G, Langford CA, Hoffman GS.

Medicine (Baltimore). 2007 Sep;86(5):269-77.

11.

Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy.

Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, Gosiengfiao Y, Gracia CR.

Fertil Steril. 2013 Feb;99(2):477-83. doi: 10.1016/j.fertnstert.2012.09.039. Epub 2012 Oct 18.

12.

Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis.

Brouwer J, Laven JS, Hazes JM, Schipper I, Dolhain RJ.

Arthritis Care Res (Hoboken). 2013 Sep;65(9):1534-8. doi: 10.1002/acr.22013.

13.

Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.

Anderson RA, Rosendahl M, Kelsey TW, Cameron DA.

Eur J Cancer. 2013 Nov;49(16):3404-11. doi: 10.1016/j.ejca.2013.07.014. Epub 2013 Aug 19.

14.
15.

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.

Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS.

Arthritis Rheum. 2001 May;44(5):1149-54.

16.

Ovarian function in Duarte galactosemia.

Badik JR, Castañeda U, Gleason TJ, Spencer JB, Epstein MP, Ficicioglu C, Fitzgerald K, Fridovich-Keil JL.

Fertil Steril. 2011 Aug;96(2):469-473.e1. doi: 10.1016/j.fertnstert.2011.05.088. Epub 2011 Jun 29.

17.

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L; French Vasculitis Study Group.

N Engl J Med. 2008 Dec 25;359(26):2790-803. doi: 10.1056/NEJMoa0802311.

18.

Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve.

Gleicher N, Weghofer A, Barad DH.

Fertil Steril. 2010 Dec;94(7):2824-7. doi: 10.1016/j.fertnstert.2010.04.067. Epub 2010 Jun 11.

PMID:
20538269
19.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.

Arthritis Rheum. 2005 Aug;52(8):2461-9.

20.

Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy.

Aikawa NE, Sallum AM, Pereira RM, Suzuki L, Viana VS, Bonfá E, Silva CA.

Clin Exp Rheumatol. 2012 May-Jun;30(3):445-9. Epub 2012 Jun 26.

PMID:
22703605
Items per page

Supplemental Content

Write to the Help Desk